We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia
News

MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia

MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia
News

MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that a first scientific publication on the Company's novel, proprietary antibody platform Ylanthia was published in the current issue of "mAbs".

The article titled "A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties" describes for the first time the detailed design, generation and testing of the Ylanthia library.

Ylanthia became commercially available for existing and new partners in 2012 and is currently used in two commercial agreements.

"Ylanthia sets new standards for therapeutic antibody generation. Its unique and innovative design translates into unprecedented structural diversity which is expected to result in antibodies against previously inaccessible target molecules and covering a unique epitope space. Furthermore, our scientists introduced an entirely new concept to improve biophysical characteristics that are relevant for antibody selection, manufacturing and administration, finally leading to better drugs," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

To confirm the functionality and quality of the Ylanthia antibody library, phage selections against several antigens were performed.

Subsequent antibody characterization revealed broad diversity and significantly improved biophysical properties including a very low aggregation tendency, increased thermodynamic stability and favorable solubility of Ylanthia antibodies.

Ylanthia comprises more than 100 billion distinct, fully human antibodies, which makes it the industry's largest known antibody Fab library. It uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into very broad structural diversity.

Ylanthia's antibody frameworks were pre-selected for favorable expression levels, stability and aggregation behavior.

A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody products, making them more cost-effective to produce.

A higher solubility in turn opens up the path for more convenient ways of administration, to the benefit of patients.

When needed, antibodies from the Ylanthia library are optimized using MorphoSys's proprietary Slonomics technology.

Slonomics enables optimization of Ylanthia antibodies with unprecedented speed and flexibility.

Advertisement